These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
119 related articles for article (PubMed ID: 32168252)
21. Treatment of metastatic Vipoma by liver transplantation. Bramley PN; Lodge JP; Losowsky MS; Giles GR Clin Transplant; 1990 Oct; 4(5 part 1):276-8; discussion 279. PubMed ID: 10150088 [TBL] [Abstract][Full Text] [Related]
22. [The somatostatin analog SMS 201-995 in long-term treatment of vipoma]. Christensen C Ugeskr Laeger; 1990 Dec; 152(51):3851-3. PubMed ID: 2177234 [TBL] [Abstract][Full Text] [Related]
23. [Mixed endocrine tumor of the pancreas (vipoma, glucagonoma). Treatment by somatostatin followed by one of its long-acting analogs]. Kaloustian E; Guillauseau PJ; Chayvialle JA; Veyssier P; Lallement PY; Latrive JP; Zylberait D; Lubetzki J Presse Med; 1987 Dec; 16(44):2217-20. PubMed ID: 2893369 [TBL] [Abstract][Full Text] [Related]
24. Capecitabine and Temozolomide as a Promising Therapy for Advanced Thymic Atypical Carcinoid. Wang X; Li Y; Duan J; Chen Y; Yuan B; Qi Z; Tan H Oncologist; 2019 Jun; 24(6):798-802. PubMed ID: 30413666 [TBL] [Abstract][Full Text] [Related]
25. Combinative treatment of transarterial chemoembolization, celecoxib and lanreotide in unresectable hepatocellular carcinoma. Tong H; Li X; Wei B; Tang C Clin Res Hepatol Gastroenterol; 2015 Oct; 39(5):e65-6. PubMed ID: 25746137 [No Abstract] [Full Text] [Related]
26. The safety of lanreotide for neuroendocrine tumor. Godara A; Siddiqui NS; Byrne MM; Saif MW Expert Opin Drug Saf; 2019 Jan; 18(1):1-10. PubMed ID: 30582380 [TBL] [Abstract][Full Text] [Related]
27. Somatostatin and analogues in the treatment of VIPoma. O'Dorisio TM; Gaginella TS; Mekhjian HS; Rao B; O'Dorisio MS Ann N Y Acad Sci; 1988; 527():528-35. PubMed ID: 2898913 [No Abstract] [Full Text] [Related]
28. Extensive metastatic ependymoma with long-term progression-free survival with capecitabine plus temozolomide combination chemotherapy: A case report. Hendem E; Korkmaz M; Araz M; Eryılmaz MK; Çağlayan D; Ayçiçek ST; Kaya B; Artaç M J Cancer Res Ther; 2024 Jul; 20(5):1625-1627. PubMed ID: 39412934 [TBL] [Abstract][Full Text] [Related]
29. Escape of the response to a long-acting somatostatin analogue (SMS 201-995) in patients with VIPoma. Koelz A; Kraenzlin M; Gyr K; Meier V; Bloom SR; Heitz P; Stalder H Gastroenterology; 1987 Feb; 92(2):527-31. PubMed ID: 2878857 [TBL] [Abstract][Full Text] [Related]
30. [Vipoma. 9-year observations using currently available therapy methods]. Zimmermann K; Rapp T; Binder J; Frölich J; Bode JC Dtsch Med Wochenschr; 1986 Feb; 111(8):298-301. PubMed ID: 2868874 [TBL] [Abstract][Full Text] [Related]
31. Long-term treatment of thyrotropin-secreting microadenoma with lanreotide and cabergoline. Pichler R; Maschek W Eur J Endocrinol; 2001 Feb; 144(2):179-80. PubMed ID: 11182755 [No Abstract] [Full Text] [Related]
33. Long-acting depot lanreotide in the treatment of patients with advanced neuroendocrine tumors. Ricci S; Antonuzzo A; Galli L; Orlandini C; Ferdeghini M; Boni G; Roncella M; Mosca F; Conte PF Am J Clin Oncol; 2000 Aug; 23(4):412-5. PubMed ID: 10955874 [TBL] [Abstract][Full Text] [Related]
34. Diagnosis and treatment of VIPoma in a female patient. Remme CA; de Groot GH; Schrijver G Eur J Gastroenterol Hepatol; 2006 Jan; 18(1):93-9. PubMed ID: 16357627 [TBL] [Abstract][Full Text] [Related]
35. Metastatic pancreatic vipoma: a case report of clinical response following treatment with corticosteroids and actinomycin D. Fennelly JJ; Cantwell B; Fielding JF; FitzGerald O; Collins PG; Buchanan KD Clin Oncol; 1982 Jun; 8(2):167-70. PubMed ID: 6286202 [No Abstract] [Full Text] [Related]
36. Evaluating lanreotide as maintenance therapy after first-line treatment in patients with non-resectable duodeno-pancreatic neuroendocrine tumours. Lepage C; Dahan L; Bouarioua N; Toumpanakis C; Legoux JL; Le Malicot K; Guimbaud R; Smith D; Tougeron D; Lievre A; Cadiot G; Di Fiore F; Bouhier-Leporrier K; Hentic O; Faroux R; Pavel M; Borbath I; Valle JW; Rinke A; Scoazec JY; Ducreux M; Walter T Dig Liver Dis; 2017 May; 49(5):568-571. PubMed ID: 28292641 [TBL] [Abstract][Full Text] [Related]
37. Phase II study of lapatinib and capecitabine in second-line treatment for metastatic pancreatic cancer. Wu Z; Gabrielson A; Hwang JJ; Pishvaian MJ; Weiner LM; Zhuang T; Ley L; Marshall JL; He AR Cancer Chemother Pharmacol; 2015 Dec; 76(6):1309-14. PubMed ID: 26507197 [TBL] [Abstract][Full Text] [Related]
38. Capecitabine and Temozolomide in Patients with Advanced Pulmonary Carcinoid Tumours. Papaxoinis G; Kordatou Z; McCallum L; Nasralla M; Lamarca A; Backen A; Nonaka D; Mansoor W Neuroendocrinology; 2020; 110(5):413-421. PubMed ID: 31437838 [TBL] [Abstract][Full Text] [Related]
39. Effects of CAPTEM (Capecitabine and Temozolomide) on a Corticotroph Carcinoma and an Aggressive Corticotroph Tumor. Nakano-Tateno T; Satou M; Inoshita N; van Landeghem FKH; Easaw J; Mehta V; Tateno T; Chik CL Endocr Pathol; 2021 Sep; 32(3):418-426. PubMed ID: 32833164 [TBL] [Abstract][Full Text] [Related]